SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Supriya Lifescience - Quaterly Results

12 Aug 2022 Evaluate
The sales for the June 2022 quarter moved up 31.73% to Rs. 1013.55 millions as compared to Rs. 769.42 millions during the corresponding quarter last year.The Net Profit of the company reported a remarkable increase of 226.27% to Rs. 252.50  millions  from Rs. 77.39 millions in previous same quarter.Operating profit surged to 336.03 millions from the corresponding previous quarter of 173.92 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 1013.55 769.42 31.73 1013.55 769.42 31.73 5300.49 3912.45 35.48
Other Income 23.57 19.39 21.56 23.57 19.39 21.56 75.77 49.77 52.24
PBIDT 336.03 173.92 93.21 336.03 173.92 93.21 2215.62 1781.51 24.37
Interest 5.81 9.74 -40.35 5.81 9.74 -40.35 41.98 40.80 2.89
PBDT 330.22 164.18 101.13 330.22 164.18 101.13 2173.64 1740.71 24.87
Depreciation 28.85 24.77 16.47 28.85 24.77 16.47 101.18 67.61 49.65
PBT 301.37 139.41 116.18 301.37 139.41 116.18 2072.46 1673.10 23.87
TAX 48.87 62.02 -21.20 48.87 62.02 -21.20 554.35 437.16 26.81
Deferred Tax 3.00 45.97 -93.47 3.00 45.97 -93.47 32.46 6.94 367.72
PAT 252.50 77.39 226.27 252.50 77.39 226.27 1518.11 1235.94 22.83
Equity 160.96 146.37 9.97 160.96 146.37 9.97 160.97 146.37 9.97
PBIDTM(%) 33.15 22.60 46.67 33.15 22.60 46.67 41.80 45.53 -8.20

Supriya Lifescience Share Price

649.75 21.75 (3.46%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×